SARS-CoV-2 Seropositivity and Subsequent Infection Risk in Healthy Young Adults: a Prospective Cohort Study
Overview
Authors
Affiliations
Background: Whether young adults who are infected with SARS-CoV-2 are at risk of subsequent infection is uncertain. We investigated the risk of subsequent SARS-CoV-2 infection among young adults seropositive for a previous infection.
Methods: This analysis was performed as part of the prospective COVID-19 Health Action Response for Marines study (CHARM). CHARM included predominantly male US Marine recruits, aged 18-20 years, following a 2-week unsupervised quarantine at home. After the home quarantine period, upon arrival at a Marine-supervised 2-week quarantine facility (college campus or hotel), participants were enrolled and were assessed for baseline SARS-CoV-2 IgG seropositivity, defined as a dilution of 1:150 or more on receptor-binding domain and full-length spike protein ELISA. Participants also completed a questionnaire consisting of demographic information, risk factors, reporting of 14 specific COVID-19-related symptoms or any other unspecified symptom, and brief medical history. SARS-CoV-2 infection was assessed by PCR at weeks 0, 1, and 2 of quarantine and participants completed a follow-up questionnaire, which included questions about the same COVID-19-related symptoms since the last study visit. Participants were excluded at this stage if they had a positive PCR test during quarantine. Participants who had three negative swab PCR results during quarantine and a baseline serum serology test at the beginning of the supervised quarantine that identified them as seronegative or seropositive for SARS-CoV-2 then went on to basic training at Marine Corps Recruit Depot-Parris Island. Three PCR tests were done at weeks 2, 4, and 6 in both seropositive and seronegative groups, along with the follow-up symptom questionnaire and baseline neutralising antibody titres on all subsequently infected seropositive and selected seropositive uninfected participants (prospective study period).
Findings: Between May 11, 2020, and Nov 2, 2020, we enrolled 3249 participants, of whom 3168 (98%) continued into the 2-week quarantine period. 3076 (95%) participants, 2825 (92%) of whom were men, were then followed up during the prospective study period after quarantine for 6 weeks. Among 189 seropositive participants, 19 (10%) had at least one positive PCR test for SARS-CoV-2 during the 6-week follow-up (1·1 cases per person-year). In contrast, 1079 (48%) of 2247 seronegative participants tested positive (6·2 cases per person-year). The incidence rate ratio was 0·18 (95% CI 0·11-0·28; p<0·001). Among seropositive recruits, infection was more likely with lower baseline full-length spike protein IgG titres than in those with higher baseline full-length spike protein IgG titres (hazard ratio 0·45 [95% CI 0·32-0·65]; p<0·001). Infected seropositive participants had viral loads that were about 10-times lower than those of infected seronegative participants (ORF1ab gene cycle threshold difference 3·95 [95% CI 1·23-6·67]; p=0·004). Among seropositive participants, baseline neutralising titres were detected in 45 (83%) of 54 uninfected and in six (32%) of 19 infected participants during the 6 weeks of observation (ID50 difference p<0·0001).
Interpretation: Seropositive young adults had about one-fifth the risk of subsequent infection compared with seronegative individuals. Although antibodies induced by initial infection are largely protective, they do not guarantee effective SARS-CoV-2 neutralisation activity or immunity against subsequent infection. These findings might be relevant for optimisation of mass vaccination strategies.
Funding: Defense Health Agency and Defense Advanced Research Projects Agency.
Trimbake D, Singh D, K Y, Babar P, S V, Tripathy A J Immunol Res. 2025; 2025:9743866.
PMID: 39963186 PMC: 11832264. DOI: 10.1155/jimr/9743866.
Post-COVID-19 manifestations among college students: shedding the light on young adults' health.
Alkhormani A, Alghamdi R, Damdam Y, Almaghrabi M, Alamri F, Khan M BMC Public Health. 2024; 24(1):3613.
PMID: 39736592 PMC: 11684266. DOI: 10.1186/s12889-024-20925-8.
Clinical and functional assessment of SARS-CoV-2 sequelae among young marines - a panel study.
Porter C, Beckett C, Cooper E, White L, Wallace D, Jakubski S Lancet Reg Health Am. 2024; 39:100909.
PMID: 39507365 PMC: 11539644. DOI: 10.1016/j.lana.2024.100909.
Liu P, Sablon 3rd O, Wang Y, Hilton S, Khalil L, Ingersoll J Front Med (Lausanne). 2024; 11:1417967.
PMID: 39323476 PMC: 11423543. DOI: 10.3389/fmed.2024.1417967.
Evaluating the risk of SARS-CoV-2 reinfection with the Omicron or Delta variant in Wales, UK.
Postans M, Pacchiarini N, Song J, Cottrell S, Williams C, Beazer A PLoS One. 2024; 19(9):e0309645.
PMID: 39240934 PMC: 11379141. DOI: 10.1371/journal.pone.0309645.